A. Niraparib appears to be most effective for patients with HRD-proficient cells B. Niraparib is only FDA approved to treat recurrent ovarian cancer C. Niraparib appears to cause more vomiting when compared with other PARP inhibitors D. Weight/platelet count-based dosing significantly decreases grade 3/4 thrombocytopenia E. Unsure

A. Olaparib plus bevacizumab has the greatest efficacy among patients with HRD-positive tumors B. BRCA-WT tumors do not appear to derive benefit from the addition of olaparib to bevacizumab C. Providers should only use olaparib and bevacizumab in patients who have platinum-resistant disease D. This combination shows significant benefit to overall survival as maintenance therapy for advanced ovarian cancer E. Unsure

A. Ovarian cancer has the highest PD-L1 expression among all gynecologic malignancies B. High mutational burden is associated with lower possibility of response to immunotherapy C. Pembrolizumab had the first site-agnostic FDA approval for MSI-H/dMMR disease D. Nivolumab has overall survival benefit for endometrioid endometrial adenocarcinoma E. Unsure

A. Hypertension B. Thrombocytopenia C. Secondary malignancy D. Acneiform rash E. Unsure

A. Lenvatinib is available as 20 mg tablets, which can be split in half B. The KEYNOTE-146 trial justified use in patients with ECOG PS 0-3 C. Lenvatinib is approved for use in this population with nivolumab D. Patients with a CrCl less than 30 ml/min require a lower starting dose E. Unsure